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Spotlight
CAPAM: The mRNA
Cap Adenosine
N6-Methyltransferase
Victoria H. Cowling1,*
The mRNA cap is a structure that
protects mRNA from degradation
and recruits processing and trans-
lation factors. A new mRNA cap-
ping enzyme has been identiﬁed,
PCIF1/CAPAM, which methylates
adenosine when it is the ﬁrst
transcribed nucleotide. This dis-
covery is crucial for understanding
the function of cap adenosine
methylation.
During eukaryotic gene expression, pre-
mRNA is modiﬁed, spliced, and exported
into the cytoplasm where it is translated
into protein. BecausemRNA constitutes a
small proportion of cellular RNA it requires
a mark of identity – amethylated structure
at the 50 terminus called the mRNA cap –
to be selected for mRNA-speciﬁc proc-
essing and translation [1,2]. The cap
structure varies in different species: in
mammals the predominant form is
denoted m7G(50)ppp(50)Xm, in which 7-
methylguanosine (m7G) is linked to the
ﬁrst transcribed nucleotide (X) via a 50 to
50 triphosphate bridge, and the ﬁrst tran-
scribed nucleotide is methylated (m) at
the ribose O2 position. If the ﬁrst tran-
scribed nucleotide is adenosine it can
be further methylated on the N6 position.
The mRNA cap speciﬁcally forms on the
ﬁrst nucleotides of RNA transcribed by
RNA polymerase II (Pol II), including pre-
mRNA, because the capping enzymes
are recruited to phospho-RNA Pol II dur-
ing transcription (Figure 1). The mRNA
cap protects pre-mRNA from nucleases,
recruits cap-binding proteins involved in
RNA processing and translation initiation,
and protects mRNA from attack by the
innate immune response. A novel cap
methyltransferase, PCIF1/CAPAM, was
recently identiﬁed [3–6]. These ﬁndings
and their implications for gene expression
control are discussed here.
The discovery of the mRNA cap began in
viruses and mammalian cells using mass
spectrometry and biochemistry [1]. The
crucial role of the cap in mRNA stability,
processing, and translation was initially
revealed using in vitro assays. However,
to understand the role of the different cap
modiﬁcations it is essential to identify the
enzymes involved. This allows the
capping enzyme and the pre-mRNA
modiﬁcation it catalyses to be ablated in
cells, and the impact on gene expression
and cell function to be determined.
Because many RNA processing events
are mechanistically linked to the pro-
cesses which occur before and after
(transcription and capping, capping and
splicing, etc.), it is important to analyse
RNA processing mechanisms in intact
cells. The enzymes which initiate cap for-
mation are present in all eukaryotes and
have been most extensively investigated
in yeast species. However, some cap
modiﬁcations, including methylation of
the ﬁrst transcribed nucleotide, are
restricted to higher eukaryotes, and per-
haps as a result the enzymes responsible
have been elusive.
Recently a novel cap methyltransferase
was discovered; CAPAM (cap-speciﬁc
adenosine N6-methyltransferase), which
catalyses N6-methylation of the ﬁrst tran-
scribed nucleotide adenosine to create
the cap structure m7G(50)ppp(50)m6Am
[3–6] (Figure 1). m7G(50)ppp(50)m6Am is
an abundant cap, and therefore has the
potential to be biologically important. In
HEK293T cells, 92% of mRNA initiating
with adenosine has a m7G(50)ppp(50)
m6Am cap, although this can ﬂuctuate
in different cell lineages [3–7]. Further-
more, mRNAs starting with m7G(50)ppp
(50)m6Am are on averagemore stable and
highly expressed than mRNAs with other
caps [4]. CAPAM was previously identi-
ﬁed as PCIF1 [human phosphorylated C-
terminal domain (CTD)-interacting factor
1], and was found to negatively impact on
RNA Pol II-dependent transcription [8]. All
recent studies agree that CAPAM is the
only cap-speciﬁc adenosine N6-methyl-
transferase [3–6]. Furthermore, CAPAM
does not methylate adenosine residues
in the RNA body [3–6].
On comparing the structures of
CAPAM to the other mammalian cap
methyltransferases (RNMT, CMTR1,
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CMTR2), the catalytic domains are
observed to have homology; however,
the surrounding regions vary, indicating
different mechanisms of action and regu-
lation [2,3]. CAPAM has a catalytic sub-
unit containing a methyltransferase
domain which has a canonical Rossmann
fold with a conserved catalytic motif and a
‘helical domain’ consisting of multiple
helices and b-sheets [3]. The helical
domain is intriguing because it does not
have overt homology to other solved
structures. As with the ﬁrst nucleotide
ribose O2-methyltransferase, CMTR1,
CAPAM has aWWdomain through which
it interacts with the serine-5 phosphory-
lated CTD of RNA Pol II [2,3] (Figure 1).
The identiﬁcation of CAPAM as the cap
adenosine N6-methyltransferase has
begun to reveal important facets of
m7G(50)ppp(50)m6A cap function. Aki-
chika et al. noted little impact of CAPAM
knockout on cell proliferation under nor-
mal tissue culture conditions [3]. How-
ever, a signiﬁcant proliferative defect
was observed under conditions of oxida-
tive stress, and it may be that CAPAM has
a prominent biological role in specialised
cell functions or in speciﬁc cell lineages.
Previously m7G(50)ppp(50)m6Am had
been found to stabilise transcripts [9].
Following CAPAM knockout, Akichika
et al. observed slight increases and
decreases in steady-state mRNA levels.
mRNAs starting with an adenosine were
increased with respect to other mRNAs,
suggesting that CAPAM or m7G(50)ppp
(50)m6Am represses these transcripts
(decreasing transcription or RNA stability)
[3]. Sendinc et al. also reported increases
and decreases in mRNA expression on
ablation of CAPAM, and these correlated
with changes in transcription rather than
in RNA stability [5]. These CAPAM-
dependent changes in transcription were
independent of m7G(50)ppp(50)m6Am,
suggesting either
indirect effects of adenosine N6-methyl-
ation or methyltransferase-independent
impacts of CAPAM. Of note, the guano-
sine cap N7-methyltransferase, RNMT–
RAM, has methyltransferase-indepen-
dent effects on transcription [10].
Because CAPAM binds to RNA Pol II, it
may also have methyltransferase-
independent effects on transcription.
Indeed, in 2008 Hirose et al. reported that
PCIF1 negatively regulates transcription,
although the mechanism remains unclear
[8]. Boulias et al. [4] noted that changes in
mRNA expression following CAPAM
knockout depended on the basal mRNA
expression level. High-abundance, stable
m7G(50)ppp(50)m6Am-capped mRNAs
did not signiﬁcantly change in expression
following CAPAM knockout, whereas
low-abundance and less-stable m7G(50)
ppp(50)m6Am-capped mRNAs were
reduced. Although these studies appear
somewhat contradictory in detail, CAPAM
clearly has direct and indirect impacts on
RNA stability and transcription, the net
output of which may depend on subtle
changes in cell physiology.
The impact of CAPAM on translation was
also investigated. Akichika et al. observed
that CAPAM knockout decreased the
translation of a subset of mRNAs which
are enriched for them7G(50)ppp(50)m6Am
cap [3]. The fact that not all translationally
repressed mRNAs contain the m7G(50)
ppp(50)m6Am cap again suggests direct
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Figure 1. mRNA Capping Enzymes Recruited to RNA Polymerase II (Pol II) During Transcription. During the initial phase of transcription, TFIIH
phosphorylates the Pol II C-terminal domain (CTD) on serine 5. The capping enzymes RNGTT, RNMT–RAM, CMTR1, and CAPAM are then recruited to the
phosphorylated RNA Pol II. Next to each capping enzyme is a cap structure that they produce, with the speciﬁc component added marked in red. RNA is synthesised
with a 50 triphosphate. RNGTT is a triphosphatase and guanylyltransferase that adds the inverted guanosine cap to nascent RNA. The other enzymes, RNMT-RAM,
CMTR1 and CAPAM, are methyltransferases. RNA is depicted as a purple strand.
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and indirect impacts of CAPAM. In other
studies using reporter constructs and
RNAs, the presence of the m7G(50)ppp
(50)m6Am cap had the opposite or mini-
mal effect on translation [5,9]. Thus the
m7G(50)ppp(50)m6Am may have gene-
and cell-speciﬁc impacts. Sendinc et al.
report that ﬁrst-nucleotide adenosine
methylation decreases binding to eIF4E,
a cap-binding protein that promotes ribo-
somal subunit recruitment [5]. The list of
cap-binding proteins which impact on
translation is continually increasing, and
it may be that cap adenosine methylation
alters the relative afﬁnity for these pro-
teins, which could explain the observed
differential effects of CAPAM on transla-
tion [2,3,5].
In summary, the identiﬁcation of CAPAM
as the ﬁrst-nucleotide adenosine N6-
methyltransferase is a major ﬁnding which
will allow the biological function of this
modiﬁcation to be uncovered. Once the
physiological processes in which CAPAM
has an inﬂuential role are identiﬁed, the
impact of this enzyme and the m7G[110_TD$DIFF](50)
ppp(50)m6Am cap on gene expression
may be clariﬁed.
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tsRNAs: The Swiss
Army Knife for
Translational Regulation
Junchao Shi,1,3
Yunfang Zhang,1,2,3
Tong Zhou,1,* and Qi Chen1,*
tRNA-derived small RNAs
(tsRNAs, or tRFs) are a new cate-
gory of regulatory noncoding
RNAs with versatile functions.
Recent emerging studies have
begun to unveil distinct features
of tsRNAs based on their
sequence, RNA modiﬁcations,
and structures that differentially
impact their functions towards
regulating multiple aspects of
translational control and ribosome
biogenesis.
The Expanding Functions of
tsRNAs
tRNAs are a type of highly modiﬁed and
structured RNA that have a well-deﬁned
role in mRNA translation. The fragmen-
tation of tRNAs at different loci gives birth
to a new species of [180_TD$DIFF]small RNAs: tsRNAs
(also known as tRNA-derived fragments,
tRFs) with unexpected complexity, which
is due, in part, to the numerous types of
RNA modiﬁcations inherited from tRNAs
as well as to the RNA interaction poten-
tial (e.g., RNAs and proteins) endowed
by RNA modiﬁcations and novel struc-
tures [1]. tsRNAs show diverse functions,
ranging from stress response, tumori-
genesis, stem cell biology, and epige-
netic inheritance [1]. At the molecular
level, recent converging studies have
begun to provide evidence that different
tsRNAs interplay with multifaceted
aspects of translational regulation and
ribosome biogenesis, which involve their
sequence speciﬁcity, RNA modiﬁcations,
and structural effects. Since tsRNAs are
at relatively low abundance compared
with their corresponding full-length
tRNAs, these emerging studies reinforce
the idea that tRNA fragmentation in
translation interference merely due to
tRNA destruction is an oversimpliﬁed
model, instead indicating a novel layer
of regulation repurposed by the genera-
tion of various functional tsRNAs.
Interfering Translational Initiation
and the Role of tsRNA Structure
and/or Modiﬁcation
The function of tsRNA in translational
inhibition was documented in early stud-
ies by Paul Anderson's group (reviewed
in [1]). They found that, under stress, the
cleavage of tRNAs at the anticodon by
the nuclease angiogenin generates 50
and 30 tsRNAs and that the 50tsRNAs,
but not 30tsRNAs, could inhibit global
protein synthesis [1]. Recently, it was
further found that two tsRNAs
[50tsRNA-Ala and -Cys, 30 nucleotides
(nt)] with a terminal oligo-G motif (TOG),
Trends in Biochemical Sciences, March 2019, Vol. 44, No. 3 185
